Chong Kun Dang, Hanmi, Donga ST, Jeil, Boryeong, Daewon, etc. new products launched
As generics of the SGLT-2 diabetes treatment drug Forxiga (Dapagliflozin, AstraZeneca) were released simultaneously on the 8th, the related market is expected to intensify. Last year, outpatient prescription sales of Xigduo, a single drug combining Forxiga and Metformin, were 91.4 billion won (Forxiga's sales were 48.5 billion won, Xigduo's sales were 42.9 billion won), and a large market is forming. From the 8th, a total of 149 items (89 single drugs, 60 complex drugs) of Dapagliflozin will be covered by insurance, and fierce competition will unfold for the 90 billion won market.

According to the industry on the